Cytokine/chemokine dysregulation in progressive MS patient is apparent and can be modulated by calpain inhibition.

This study examines the cytokine/chemokine profile of a 62-year-old African American male with progressive multiple sclerosis (MS). MRI images of the MS patient demonstrated generalized white matter involvement with multiple lesions in the periventricular area. A 42-plex Discovery Assay® (Eve Technologies) of the patient's plasma and peripheral blood mononuclear cells (PBMCs) supernatant or PBMC-derived T cell supernatant samples from two separate clinic visits revealed vastly differing cytokine/chemokine levels. In addition, certain cytokine/chemokine profiles had notable differences when compared to the larger patient group or patients' PBMCs treated with a calpain inhibitor in vitro. Interestingly, large numbers of cytokines/chemokines and growth factors in MS PBMCs are modulated by calpain inhibition, suggesting the clinical significance of these findings in designing better therapeutics against progressive MS.

Citation

Rachel Polcyn, Mollie Capone, Denise Matzelle, Brittany Lueking, Aljoeson Walker, Elizabeth Kau, Azizul Haque, Naren Banik. Cytokine/chemokine dysregulation in progressive MS patient is apparent and can be modulated by calpain inhibition. Metabolic brain disease. 2020 Feb;35(2):255-261

Mesh Tags

Substances

PMID: 31853829

search → result